Erasca To Present Preliminary SEACRAFT-1 Phase 1 Data For Naporafenib Plus Trametinib In RAS Q61X Mutant Solid Tumors As Oral Presentation At 36th EORTC-NCI-AACR Symposium
Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium
Bullish Erasca Insiders Loaded Up On US$3.97m Of Stock
Erasca, Inc. (NASDAQ:ERAS) Is Favoured by Institutional Owners Who Hold 61% of the Company
Erasca to Present at Upcoming Investor Conferences in September
Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $3
We're Hopeful That Erasca (NASDAQ:ERAS) Will Use Its Cash Wisely
HC Wainwright & Co. Maintains Buy on Erasca, Raises Price Target to $6
Erasca Analyst Ratings
Goldman Sachs Maintains Erasca(ERAS.US) With Buy Rating, Cuts Target Price to $3
Goldman Sachs analyst Chris Shibutani maintains $Erasca(ERAS.US)$ with a buy rating, and adjusts the target price from $4 to $3.According to TipRanks data, the analyst has a success rate of 44.9%
Erasca Inc. Poised for Growth: Buy Rating Maintained Amidst Promising Trial Updates and Solid Financials
Erasca GAAP EPS of -$0.29
Morgan Stanley Maintains Erasca(ERAS.US) With Buy Rating, Cuts Target Price to $4
Morgan Stanley analyst Jeffrey Hung maintains $Erasca(ERAS.US)$ with a buy rating, and adjusts the target price from $15 to $4.According to TipRanks data, the analyst has a success rate of 52.3% and
Morgan Stanley Keeps Their Buy Rating on Erasca (ERAS)
H.C. Wainwright Maintains Erasca(ERAS.US) With Buy Rating, Raises Target Price to $6
H.C. Wainwright analyst Andres Y. Maldonado maintains $Erasca(ERAS.US)$ with a buy rating, and adjusts the target price from $5 to $6.According to TipRanks data, the analyst has a success rate of 40.7
Erasca's Innovative Melanoma Treatments Prompt Buy Rating
Erasca, Inc.: A Strong Buy on Robust Pipeline and Promising Clinical Data
Erasca | 10-Q: Q2 2024 Earnings Report
Erasca: Cash, Cash Equivalents, and Marketable Securities Expected to Fund Ops Into 1H of 2027 >ERAS